Marissa Love, MD
Allergy & Immunology · Kansas City, KSNPI 1427494202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,951 of the $4,213 with a category attached, or 70.0%. 25 manufacturers reported payments, led by AstraZeneca at 46.3% of the total. Reporting peaked in 2024 at $2,510 and has fallen 54.6% since, to $1,138 in 2025.
Across 90 payments — averaging $46.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Astrazeneca UK Limited$398
- Regeneron Healthcare Solutions, Inc.$347
- GSK$281
- Pfizer$147
- Takeda Pharmaceuticals U.S.A., Inc.$139
- plus $949 from 19 others
Across 1 payment — averaging $23,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$24K
What the payments were for
- Consulting fees$150%
- Travel & lodging$1,24730%
- Food & beverage$2,95170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $1,952 |
| Astrazeneca UK Limited | 2 | $398 |
| Regeneron Healthcare Solutions, Inc. | 11 | $347 |
| GSK | 11 | $281 |
| Pfizer | 4 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
| Sanofi | 4 | $124 |
| Biocryst US Sales Co., LLC | 1 | $122 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Grifols USA, LLC | 3 | $118 |
| Blueprint Medicines Corporation | 1 | $107 |
| Amgen | 3 | $59 |
| CSL Behring | 2 | $40 |
| Hospira, Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| Genentech, Inc. | 1 | $28 |
| Novartis | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Optinose US, Inc. | 1 | $16 |
| ADMA Biomanufacturing LLC | 1 | $15 |
| Incyte Corporation | 1 | $14 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,213 in reported general payments places this provider in the 65th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AscenivImmune Globulin,gamma(Igg)slra | 18 | $654,218 |
| XolairOmalizumab | 32 | $92,405 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $45,068 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,915 |
| Epinephrine | 13 | $3,264 |
| Ipratropium Bromide | 58 | $1,964 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,141 |
| Mometasone Furoate | 13 | $1,025 |
| Fluticasone Propionate | 36 | $788 |
| Azelastine Hcl | 30 | $776 |
| Montelukast Sodium | 60 | $728 |
| Levocetirizine Dihydrochloride | 36 | $437 |
| Hydroxyzine Hcl | 17 | $396 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $326 |
| Famotidine | 16 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $28 | $92,40532 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $281 | $49,98475 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $3,26413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Kansas City
- Selina GiererKansas City$13K
- Damandeep WaliaKansas City$3K
- Hanh HoKansas City$2K
- Jeehyun RhaKansas City$1K
- Timothy NguyenKansas City$743
- Tomara SpiessKansas City$455
- Andrea D'melloKansas City$371
- John MartinezKansas City$76
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.